A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Eli Lilly
366 trials monitored
See 16 trials at risk
Obesity
3,903 trials monitored
See 160 trials at risk
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition. Participation in the study will last about 58 weeks.
Trial Details
NCT Number NCT07890376
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overnutrition, Overweight, Weight Loss
Enrollment 460 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov